Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121666 | 0.84 | CYP2C19 (0.53) | CYP2C19SMN1; SMN2L3MBTL1SIGMAR1TSHR | |
| SCHEMBL5130455 | 0.78 | BCHE (0.49) | CYP2C19SMN1; SMN2SIGMAR1ALDH1A1TSHR | |
| SCHEMBL3306841 | 0.78 | SIGMAR1 (0.68) | CYP2C19SMN1; SMN2SIGMAR1ALDH1A1DRD4 | |
| SCHEMBL5124876 | 0.77 | SIGMAR1 (0.57) | SIGMAR1 | |
| SCHEMBL7268908 | 0.76 | SIGMAR1 (0.79) | L3MBTL1SIGMAR1POLB | |
| SCHEMBL4848461 | 0.76 | SIGMAR1 (0.65) | CYP2C19SMN1; SMN2SIGMAR1ALDH1A1DRD4 | |
| SCHEMBL29712058 | 0.76 | SIGMAR1 (0.65) | CYP2C19SMN1; SMN2SIGMAR1ALDH1A1DRD4 | |
| SCHEMBL13453086 | 0.76 | TSHR (0.60) | CYP2C19SIGMAR1TSHRDRD4CYP2D6 | |
| SCHEMBL15992138 | 0.75 | DRD2 (0.65) | SIGMAR1DRD4DRD2DPP7 | |
| SCHEMBL20183393 | 0.75 | DRD2 (0.65) | SIGMAR1DRD4DRD2DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MUC1, CD44, TP53 | CYP2C19 4872/4885SMN1; SMN2 4158/4885L3MBTL1 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.